Results 61 to 70 of about 33,833 (238)
BMC Infectious Diseases, 2021 Background Drug-resistant tuberculosis (DR-TB) remains a major public health concern worldwide. Bedaquiline, a novel diarylquinoline, was added to the WHO-recommended all-oral regimen for patients with multidrug-resistant tuberculosis.
Ming-Gui Wang +2 more
doaj +1 more source
Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis [PDF]
, 2014 KMWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis.
Conradie, F +3 more
core
Clinical Case Reports, Volume 14, Issue 3, March 2026.Coronal reconstruction post contrast thoraco‐abdominal CT of a 9 years old boy taken December, 2023. This shows 1.45 by 3.9 cms hypodense collection having rim enhancement in the right anterio‐inferior sub‐phrenic space suggestive of abscess. ABSTRACT Diagnosing extrapulmonary and drug‐resistant tuberculosis in children is challenging.
Animaw Lingerew +4 more
wiley +1 more source
Antimicrobial Agents and ChemotherapyMycobacterium avium, a leading nontuberculous mycobacterium (NTM) pathogen, causes chronic pulmonary infections, particularly in individuals with underlying lung conditions or immunosuppression.
Binayak Rimal +3 more
semanticscholar +1 more source
Emerging Challenges and Opportunities in Infectious Disease Epidemiology. [PDF]
, 2019 Much of the intellectual tradition of modern epidemiology stems from efforts to understand and combat chronic diseases persisting through the 20th century epidemiologic transition of countries such as the United States and United Kingdom.
Lewnard, Joseph A, Reingold, Arthur L
core
Quality of outcome reporting in phase II studies in pulmonary tuberculosis [PDF]
, 2015 Tuberculosis (TB) remains a major killer amongst the infectious diseases. Current treatment involves a four-drug regimen for at least 6 months. New drugs and regimens are required to shorten treatment duration, reduce toxicity and combat drug resistance,
Bonnett, Laura Jayne +1 more
core +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 3, March 2026.Abstract New drugs are urgently needed to treat drug‐resistant tuberculosis in combination regimens. Ganfeborole demonstrated bactericidal activity and good tolerability in clinical trials. In preclinical studies, ganfeborole showed embryofetal developmental effects, currently mandating highly effective non‐user dependent contraception in women of ...
Laura Iavarone +13 more
wiley +1 more source
Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis
Journal of Biosafety and BiosecurityBedaquiline resistance is increasingly observed in the treatment of rifampicin-resistant tuberculosis (TB), yet standardized regimens for managing bedaquiline-resistant TB are lacking.
Prakasini Satapathy +8 more
doaj +1 more source
International Journal of Mycobacteriology, 2020 Background: Mycobacterium abscessus is notorious for being intrinsically resistant to most antibiotics. Antibiotic efflux is one of the mechanisms used by M. abscessus to pump out antibiotics from their cells.
Anandi Martin +5 more
doaj +1 more source
Classifying new anti-tuberculosis drugs: Rationale and future perspectives [PDF]
, 2016 The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter ...
Caminero Luna, JA +10 more
core